Switch studies in virologically suppressed patients

Switch to LPV/r monotherapy
OK Study: Switch LPV/r + 2NRTIs to LPV/r monotherapy
Original article : J Acquir Immune Defic Syndr. 2005 Nov 1;40(3):280-7 – JR Arribas
Last update : 28/03/2014

Dr Anton Pozniak
Chelsea and Westminster Hospital
London, UK

  • This pilot study provides preliminary evidence suggesting that in patients suppressed on a triple therapy with LPV/r, continuation with LPV/r monotherapy can maintain HIV suppression in a large proportion of patients

Design :

Endpoints: pilot study :

  • Primary outcome: proportion of patients with HIV-1 RNA < 500 c/mL at W48 (ITT analysis)
  • Secondary outcomes: proportion of patients with HIV-1 RNA < 50 c/mL at W48, time to loss of virologic suppression, development of HIV resistance, CD4 changes, safety, treatment-related adverse events

Baseline characteristics and patient disposition :

Virologic outcome :

Other outcomes :

  • 4 blips in the monotherapy group vs 1 in the triple therapy group
  • No significant changes in CD4 cell count in any group at W48
  • Median adherence was 96% in the triple therapy group and 86% in the monotherapy group (p = 0.09)
  • Loss of virologic suppression was associated with shorter time of HIV-1 RNA < 50 c/mL prior to monotherapy (median of 40 weeks vs 132 weeks in patients with maintenance of virologic suppression ; p = 0.02)
  • Patients with loss of virologic suppression on LPV/r monotherapy were safely reinduced with prior NRTIs and achieved HIV-1 RNA < 50 c/mL
  • Grade 3 hypertriglyceridemia occurred in 3 patients in the triple therapy arm vs none in the monotherapy arm. One patient in each arm had grade 3 hypercholesterolemia



Back to Table of Contents

Copyright AEI 2020 | Links | Contact | Editorial Office | Faculty and Disclosure | Terms of use aei